Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company focused on personalized cancer treatments, has announced a significant update to its Board of Directors. Jesper Høiland, a seasoned executive with over three decades of experience in the pharmaceutical industry, has been appointed to the board, effective immediately. This move comes as Joseph Vazzano prepares to step down on June 30, 2025, after two years of service.

Mr. Høiland's appointment is seen as a strategic addition to Allarity's leadership, given his extensive background in global pharmaceutical commercialization and executive roles. His tenure as President and EVP of Novo Nordisk's U.S. operations, along with leadership positions at Radius Health and Ascendis Pharma, underscores his capability to steer companies through critical phases of growth and development. Currently, he also holds board positions at SciBase Holding AB, ALK-Abello A/S, and Flen Health SA.

The transition occurs at a pivotal moment for Allarity, as the company advances its Phase 2 clinical trials for stenoparib, a novel dual PARP and WNT pathway inhibitor. Jerry McLaughlin, Chairman of the Board, expressed enthusiasm about Høiland's joining, highlighting the value of his experience during this period of clinical momentum. McLaughlin also extended gratitude to Vazzano for his contributions, particularly in strengthening the company's governance and operational focus.

Thomas Jensen, CEO of Allarity Therapeutics, remarked on the immediate impact Høiland has had since beginning his consultancy role in October 2024. Jensen emphasized Høiland's strategic advice and his deep understanding of the commercialization process for investigational drugs as key assets for Allarity's future. With Høiland's global network and leadership experience, Allarity is poised to navigate the challenges of bringing personalized cancer treatments to market.

IFK Värnamo's Allsvenskan survival hopes were extinguished on Sunday despite a dramatic stoppage-time equalizer from Marcus Antonsson against IF Brommapojkarna. The 1-1 draw at Finnvedsvallen mathematically confirmed Värnamo's relegation to Superettan with three matches remaining in the season. Victor Lind had given Brommapojkarna a late 1-0 lead with just six minutes remaining, setting the stage for Antonsson's last-gasp intervention that ultimately proved insufficient.

The result leaves Värnamo at the bottom of the table, nine points adrift of Östers IF who occupy the relegation playoff position. With Östers IF set to face fellow strugglers Degerfors IF in the next round, at least one of those clubs will reach 26 points—a tally Värnamo cannot match as their maximum possible points total stands at 25. This mathematical certainty confirms Värnamo's immediate return to the second division after three seasons in the top flight.

Värnamo's relegation marks the end of a promising top-flight journey that began with their Superettan championship in 2021. The Småland club followed their promotion with a tenth-place finish in 2022, then surprised many by finishing fifth last season before securing survival through a playoff victory against Landskrona Bois. This season's struggle has seen the team manage only one win, seven draws, and multiple losses across their campaign.

Brommapojkarna, meanwhile, secured a valuable point that strengthens their position in eleventh place, maintaining a four-point cushion above the relegation playoff spot. The Stockholm-based club made one lineup change from their previous outing, with Junior Martinsson Ngouali replacing Kåre Barslund. Värnamo coach Arne Sandstø also made an adjustment, fielding Simon Thern instead of Carl Johansson as both teams sought crucial points in their respective survival battles.